BrainCo Bionic Hand Inspires a Child’s Journey Forward
BOSTON, Oct. 28, 2025 /PRNewswire/ -- In early September, a young boy named Ma received a brand-new hand — a...
Brain
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual acuity...
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the...
Kanazawa University Research: Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells
KANAZAWA, Japan, Oct. 28, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in ACS...
Queen Square Imaging Centre: New technique could improve outcomes for essential tremor patients
BILLINGSHURST, England, Oct. 27, 2025 /PRNewswire/ -- A new study by world-leading neurosurgeons Queen Square Imaging Centre in London has...
Remedy Robotics and Mission Thrombectomy Announce Partnership to Expand Access to Thrombectomy for Stroke with Telerobotics
Remedy Robotics selected as Mission Thrombectomy's exclusive robotics partner to broaden access to life-saving stroke treatment in the U.S. and...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...
Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026
Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support CategoryWESTBROOK, Maine, Oct. 27, 2025 (GLOBE...
Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026
Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support CategoryWESTBROOK, Maine, Oct. 27, 2025 (GLOBE...
Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026
Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support CategoryWESTBROOK, Maine, Oct. 27, 2025 (GLOBE...
Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform
Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core TechnologiesJACKSON CENTER, Pa., Oct. 27, 2025...